Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 trial of V565 in active Crohn's disease
2016-002939-15Phase 2Completed
- Sponsor
- VHsquared Ltd.
- Start
- Nov 2016
- Modality
- Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2 trial of V565 in Crohn's disease, sponsored by VHsquared Ltd. Primary endpoints: Primary Efficacy Endpoint and Primary Safety and Tolerability Endpoint. Started Nov 2016; status: completed.
02
Drugs
V565
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on 2016-002939-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-002939-15.